

Carl Koschmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2790154/publications.pdf>

Version: 2024-02-01

95
papers

1,740
citations

331670

21
h-index

315739

38
g-index

102
all docs

102
docs citations

102
times ranked

2950
citing authors

#	ARTICLE	IF	CITATIONS
1	ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. <i>Science Translational Medicine</i> , 2016, 8, 328ra28.	12.4	212
2	IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	169
3	Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy. <i>Neoplasia</i> , 2014, 16, 543-561.	5.3	131
4	Integrated Metabolic and Epigenomic Reprogramming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Cell</i> , 2020, 38, 334-349.e9.	16.8	87
5	Recent advances and future of immunotherapy for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1245-1264.	3.1	57
6	Characterizing and targeting <i>PDGFRA</i> alterations in pediatric high-grade glioma. <i>Oncotarget</i> , 2016, 7, 65696-65706.	1.8	55
7	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. <i>Neuro-Oncology</i> , 2019, 21, 968-980.	1.2	52
8	Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. <i>Acta Neuropathologica</i> , 2018, 135, 299-301.	7.7	51
9	CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. <i>Acta Neuropathologica Communications</i> , 2018, 6, 80.	5.2	50
10	Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. <i>Cancer Research</i> , 2017, 77, 227-233.	0.9	46
11	Adenoviral vector-mediated gene therapy for gliomas: coming of age. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1241-1257.	3.1	44
12	Survival After Relapse of Medulloblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 269-273.	0.6	43
13	ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1167158.	0.7	41
14	Everolimus improves the efficacy of dasatinib in PDGFR α -driven glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5313-5325.	8.2	41
15	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
16	Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. <i>Neuro-Oncology</i> , 2022, 24, 1438-1451.	1.2	36
17	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, 1366-1374.	1.2	36
18	Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. <i>Current Oncology Reports</i> , 2020, 22, 19.	4.0	35

#	ARTICLE	IF	CITATIONS
19	Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma. <i>Journal of Visualized Experiments</i> , 2015, , .	0.3	33
20	ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. <i>Cell Reports</i> , 2022, 38, 110216.	6.4	32
21	Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. <i>Scientific Reports</i> , 2021, 11, 5098.	3.3	31
22	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. <i>Science Translational Medicine</i> , 2021, 13, eabc0497.	12.4	29
23	Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 6266-6276.	7.0	26
24	Brainstem Low-Grade Gliomas in Children – Excellent Outcomes With Multimodality Therapy. <i>Journal of Child Neurology</i> , 2017, 32, 194-203.	1.4	21
25	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 877-881.	7.7	21
26	Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 37.	5.2	20
27	Single vs. combination immunotherapeutic strategies for glioma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 543-554.	3.1	17
28	Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. <i>Npj Precision Oncology</i> , 2017, 1, 32.	5.4	17
29	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2163-2174.	4.1	17
30	The Emerging Role of Ras Pathway Signaling in Pediatric Cancer. <i>Cancer Research</i> , 2020, 80, 5155-5163.	0.9	17
31	BRAF activating mutations involving the $\hat{2}3\text{-}\hat{1}\pm\text{C}$ loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 24.	5.2	16
32	Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2018, 137, 155-169.	2.9	15
33	Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 555-562.	2.3	15
34	Successful treatment of a <i>TSC2</i> -mutant glioblastoma with everolimus. <i>BMJ Case Reports</i> , 2019, 12, e227734.	0.5	14
35	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	5.0	12
36	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 67.	5.2	12

#	ARTICLE	IF	CITATIONS
37	Lentiviral-Induced High-Grade Gliomas in Rats: The Effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. <i>Neurotherapeutics</i> , 2014, 11, 623-635.	4.4	10
38	Integrating RNA sequencing into neuro-oncology practice. <i>Translational Research</i> , 2017, 189, 93-104.	5.0	10
39	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-34.	3.0	10
40	Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa021.	0.7	10
41	Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma". <i>Npj Precision Oncology</i> , 2017, 1, 29.	5.4	9
42	Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. <i>Leukemia and Lymphoma</i> , 2021, 62, 1990-1994.	1.3	9
43	Characteristics of patients "10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
44	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	1.2	9
45	Cell-Free Tumor DNA (cf-tDNA) Liquid Biopsy: Current Methods and Use in Brain Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 882452.	4.8	9
46	Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. <i>Neuro-Oncology</i> , 2018, 20, 1356-1367.	1.2	8
47	Molecular characterization reveals <i>NF1</i> deletions and <i>FGFR1</i> activating mutations in a pediatric spinal oligodendroglioma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26346.	1.5	6
48	Pediatric craniopharyngioma in association with familial adenomatous polyposis. <i>Familial Cancer</i> , 2019, 18, 327-330.	1.9	6
49	Prolonged survival in a patient with a cervical spine H3K27M-mutant diffuse midline glioma. <i>BMJ Case Reports</i> , 2019, 12, e231424.	0.5	5
50	Molecular insights into malignant progression of atypical choroid plexus papilloma. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a005272.	1.2	5
51	Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. <i>Neuro-Oncology</i> , 2023, 25, 54-67.	1.2	5
52	Characteristics of children "36 months of age with DIPG: A report from the international DIPG registry. <i>Neuro-Oncology</i> , 2022, 24, 2190-2199.	1.2	4
53	Clinical Application of Whole Genome Array Improves the Diagnosis of Pediatric Brain Tumors. <i>International Journal of Surgical Pathology</i> , 2017, 25, 688-695.	0.8	3
54	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi186-vi186.	1.2	2

#	ARTICLE	IF	CITATIONS
55	HGG-32. ONC201 AND ONC206 TARGET TUMOR CELL METABOLISM IN PEDIATRIC DIFFUSE MIDLINE GLIOMA PRECLINICAL MODELS. <i>Neuro-Oncology</i> , 2021, 23, i23-i24.	1.2	2
56	Enhancing GD2 CAR-T Therapy with IGF1R Blockade: Are DIPG CAR-Ts ready for combinatorial therapy?. <i>Neuro-Oncology</i> , 2022, , .	1.2	2
57	Ultra-rapid somatic variant detection via real-time targeted amplicon sequencing. <i>Communications Biology</i> , 2022, 5, .	4.4	2
58	Loss of CDKN1C in a Recurrent Atypical Teratoid/Rhabdoid Tumor. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e466-e469.	0.6	1
59	GENE-34. MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING Acvr1 G328V. <i>Neuro-Oncology</i> , 2018, 20, vi110-vi111.	1.2	1
60	CSIG-08. DYNAMICS OF GLIOMA GROWTH: SELF-ORGANIZATION GUIDES THE PATTERNING OF THE EXTRACELLULAR MATRIX AND REGULATES TUMOR PROGRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi44-vi44.	1.2	1
61	DIPG-69. CHARACTERISTICS OF PATIENTS ≥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	1.2	1
62	Multiplatform Molecular Profiling. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 80-80.	2.0	1
63	Autopsy findings of previously described case of diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. <i>Acta Neuropathologica Communications</i> , 2021, 9, 113.	5.2	1
64	Pediatric Hematology-Oncology Case-Based Lecture Series. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 0, , .	1.2	1
65	CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii45-ii45.	1.2	1
66	DIPG-09. Diffuse Midline Glioma-Adaptive Combinatory Trial (DMG-ACT): A biology-driven platform trial in pediatric and young adult patients with diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i19-i19.	1.2	1
67	Expanding Access to CNS-TAP: Design, Development, and Initial Use of a Complex Precision Health Specialty Web App for Neuro-Oncology. <i>Studies in Health Technology and Informatics</i> , 2022, , .	0.3	1
68	Whole Genome SNP Array Improves Diagnosis and Therapy in Pediatric Brain Tumors. <i>Cancer Genetics</i> , 2016, 209, 294.	0.4	0
69	CRAN-10. PEDIATRIC CRANIOPHARYNGIOMA IN ASSOCIATION WITH FAMILIAL ADENOMATOUS POLYPOSIS. <i>Neuro-Oncology</i> , 2018, 20, i38-i39.	1.2	0
70	PDTM-29. CSF H3F3A K27M CIRCULATING TUMOR DNA COPY NUMBER QUANTIFIES TUMOR GROWTH AND TREATMENT RESPONSE. <i>Neuro-Oncology</i> , 2018, 20, vi209-vi210.	1.2	0
71	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i53-i53.	1.2	0
72	DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG. <i>Neuro-Oncology</i> , 2018, 20, i56-i56.	1.2	0

#	ARTICLE	IF	CITATIONS
73	HGG-03. EVEROLIMUS TREATMENT IMPROVES THE CNS PENETRATION AND EFFICACY OF DASATINIB IN THE TREATMENT OF PDGFRA-DRIVEN PEDIATRIC HIGH-GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii87-ii87.	1.2	0
74	HGG-08. ATRX LOSS IN PEDIATRIC GBM RESULTS IN EPIGENETIC DYSREGULATION OF G2/M CHECKPOINT MAINTENANCE AND SENSITIVITY TO ATM INHIBITION. <i>Neuro-Oncology</i> , 2019, 21, ii88-ii88.	1.2	0
75	PDTM-10. USE OF A NOVEL, HAND-HELD, ELECTRONIC DNA ANALYSIS PLATFORM TO QUANTIFY MULTI-GENE MOLECULAR RESPONSE IN CSF OF PATIENTS WITH HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi188-vi189.	1.2	0
76	PDTM-42. CROSS-PLATFORM PROFILING OF ctDNA USING ddPCR: STANDARDIZATION OF THE LIQUID BIOPSY FOR PEDIATRIC DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi196-vi196.	1.2	0
77	GENE-17. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF THE G2/M CHECKPOINT AND SENSITIVITY TO ATM INHIBITION. <i>Neuro-Oncology</i> , 2019, 21, vi101-vi101.	1.2	0
78	Integrating subgroups with mixed-type endpoints in early phase oncology trials. <i>Statistical Methods in Medical Research</i> , 2020, 29, 498-507.	1.5	0
79	DDRE-30. THERAPEUTIC TARGETING OF DISRUPTED METABOLIC STATE IN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i13-i13.	0.7	0
80	EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021, 23, i46-i46.	1.2	0
81	EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201. <i>Neuro-Oncology</i> , 2021, 23, i46-i47.	1.2	0
82	CLRM-06. COMPARISON OF INDIVIDUALIZED ANTI-CANCER THERAPY REGIMENS RECOMMENDED BY A MULTIDISCIPLINARY MOLECULARLY-DRIVEN TUMOR BOARD IN A PEDIATRIC DIPG CLINICAL TRIAL (PNOC003) VERSUS THOSE SELECTED BY THE CNS-TAP TOOL. <i>Neuro-Oncology Advances</i> , 2021, 3, iv2-iv2.	0.7	0
83	Participation in a Clinical Trial Does Not Impact Outcome in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 1318-1318.	1.4	0
84	RARE-17. SURVIVAL BENEFIT FOR INDIVIDUALS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME AND BRAIN TUMORS WHO UNDERGO SURVEILLANCE PROTOCOL. A REPORT FROM THE INTERNATIONAL REPLICATION REPAIR CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii445-iii446.	1.2	0
85	ETMR-17. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF ETMR PATIENT SAMPLES. <i>Neuro-Oncology</i> , 2020, 22, iii326-iii326.	1.2	0
86	DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG. <i>Neuro-Oncology</i> , 2020, 22, iii297-iii297.	1.2	0
87	DIPG-64. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii300-iii300.	1.2	0
88	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. <i>Neuro-Oncology</i> , 2020, 22, iii298-iii299.	1.2	0
89	PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii427-iii427.	1.2	0
90	NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. <i>Neuro-Oncology</i> , 2020, 22, ii154-ii154.	1.2	0

#	ARTICLE	IF	CITATIONS
91	DDRE-03. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii61-ii62.	1.2	0
92	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii45-ii46.	1.2	0
93	CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. <i>Neuro-Oncology</i> , 2020, 22, ii16-ii16.	1.2	0
94	DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992). <i>Neuro-Oncology</i> , 2022, 24, i18-i19.	1.2	0
95	DIPG-49. International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for DMG. <i>Neuro-Oncology</i> , 2022, 24, i29-i30.	1.2	0